Organic Letters
Letter
REFERENCES
■
(1) (a) Naret, T.; Provot, O.; Alami, M.; Hamze, A. Asian J. Org.
Chem. 2017, 6, 1509−1518. (b) Prunet, J. Angew. Chem., Int. Ed.
2003, 42, 2826−2830. (c) Barda, D. A.; Wang, Z.-Q.; Britton, T. C.;
Henry, S. S.; Jagdmann, G. E.; Coleman, D. S.; Johnson, M. P.; Andis,
S. L.; Schoepp, D. D. Bioorg. Med. Chem. Lett. 2004, 14, 3099−3102.
(2) Wagner, C. E.; Jurutka, P. W.; Marshall, P. A.; Groy, T. L.; van
der Vaart, A.; Ziller, J. W.; Furmick, J. K.; Graeber, M. E.; Matro, E.;
Miguel, B. V.; Tran, I. T.; Kwon, J.; Tedeschi, J. N.; Moosavi, S.;
Danishyar, A.; Philp, J. S.; Khamees, R. O.; Jackson, J. N.; Grupe, D.
K.; Badshah, S. L.; Hart, J. W. J. Med. Chem. 2009, 52, 5950−5966.
(3) Hamze, A.; Giraud, A.; Messaoudi, S.; Provot, O.; Peyrat, J.-F.;
Bignon, J.; Liu, J.-M.; Wdzieczak-Bakala, J.; Thoret, S.; Dubois, J.;
Brion, J.-D.; Alami, M. ChemMedChem 2009, 4, 1912−1924.
(4) Wittig, G.; Geissler, G. Liebigs Ann. Chem. 1953, 580, 44−57.
(5) Peterson, D. J. J. Org. Chem. 1968, 33, 780−784.
(6) Tebbe, F. N.; Parshall, G. W.; Reddy, G. S. J. Am. Chem. Soc.
1978, 100, 3611−3613.
(7) Julia, M.; Paris, J.-M. Tetrahedron Lett. 1973, 14, 4833−4836.
(8) (a) Lebel, H.; Paquet, V. J. Am. Chem. Soc. 2004, 126, 320−328.
́
(b) Lebel, H.; Davi, M.; Díez-Gonzalez, S.; Nolan, S. P. J. Org. Chem.
2007, 72, 144−149.
́
(9) (a) Barluenga, J.; Moriel, P.; Valdes, C.; Aznar, F. Angew. Chem.
2007, 119, 5683−5686. (b) For review see, Barluenga, J.; Valdes, C.
́
Angew. Chem., Int. Ed. 2011, 50, 7486−7500. (c) Qiu, D.; Mo, F.;
Zhang, Y.; Wang, J. Adv. Organomet. Chem. 2017, 67, 151−219. (d)
For recent reviews, see: Xia, Y.; Wang, J. Chem. Soc. Rev. 2017, 46,
2306−2362.
(10) According to the CHEM21 selection guide of classical solvents,
dioxane was classified as a hazardous solvent, while toluene represents
a problematic solvent, see Prat, D.; Wells, A.; Hayler, J.; Sneddon, H.;
McElroy, C. R.; Abou-Shehada, S.; Dunn, P. Green Chem. 2016, 18,
288−296.
(11) DCE is on the REACh authorization list and should not be
used anymore at the industrial scale in Europe, without authorization.
(12) Piontek, A.; Bisz, E.; Szostak, M. Angew. Chem., Int. Ed. 2018,
57, 11116−11128.
(13) PEG-400 is an inexpensive, biodegradable, nonhalogenated,
and nontoxic solvent, with an acute oral toxicity (LD50) of 26 800
mg/kg in rabbits.
(14) Zhao, H.; Cheng, M.; Zhang, J.; Cai, M. Green Chem. 2014, 16,
2515−2522.
(15) Chandrasekhar, S.; Narsihmulu, C.; Sultana, S. S.; Reddy, N. R.
Org. Lett. 2002, 4, 4399−4401.
(16) Xu, C.; Huang, B.; Yan, T.; Cai, M. Green Chem. 2018, 20,
391−397.
(17) Yedage, S. L.; Bhanage, B. M. Green Chem. 2016, 18, 5635−
5642.
(18) For the prepartion of the MeDavePhos·CF3SO3 ligand, please,
(19) Roche, M.; Hamze, A.; Provot, O.; Brion, J. D.; Alami, M. J.
Org. Chem. 2013, 78, 445−454.
(20) Messaoudi, S.; Treguier, B.; Hamze, A.; Provot, O.; Peyrat, J.
F.; De Losada, J. R.; Liu, J. M.; Bignon, J.; Wdzieczak-Bakala, J.;
Thoret, S.; Dubois, J.; Brion, J. D.; Alami, M. J. Med. Chem. 2009, 52,
4538−4542.
(21) Aziz, J.; Brachet, E.; Hamze, A.; Peyrat, J.-F.; Bernadat, G.;
Morvan, E.; Bignon, J.; Wdzieczak-Bakala, J.; Desravines, D.; Dubois,
J.; Tueni, M.; Yassine, A.; Brion, J.-D.; Alami, M. Org. Biomol. Chem.
2013, 11, 430−442.
(22) Shen, D.; Yu, X.; Wu, Y.; Chen, Y.; Li, G.; Cheng, F.; Xia, L.
Expert Rev. Anticancer Ther. 2018, 18, 487−499.
(23) Yoshida, H.; Shinke, A.; Kawano, Y.; Takaki, K. Chem.
Commun. 2015, 51, 10616−10619.
́
(24) Thalen, L. K.; Zhao, D.; Sortais, J.-B.; Paetzold, J.; Hoben, C.;
̈
Backvall, J.-E. Chem. - Eur. J. 2009, 15, 3403−3410.
E
Org. Lett. XXXX, XXX, XXX−XXX